The role of gemtuzumab ozogamicin in acute leukaemia therapy

British Journal of Haematology

Volumn 132, Issue 4, 2006, Pages 398-409

  Tsimberidou, Apostolia Maria ^a,b   Giles, Francis J ^a   Estey, Elihu ^a   O'Brien, Susan ^a   Keating, Michael J ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute; Acute myeloid leukaemia; Gemtuzumab; Leukaemia; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; BUSULFAN; CALICHEAMICIN; CD33 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CALICHEAMICIN GAMMA(1)I; DIFFERENTIATION ANTIGEN; ENEDIYNE; GEMTUZUMAB; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ASCITES; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CHILL; CLINICAL TRIAL; DOSE CALCULATION; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EDEMA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INDUCED HYPOTENSION; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DISEASE; LIVER VEIN; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; VEIN OCCLUSION; WEIGHT GAIN; ACUTE DISEASE; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; METABOLISM; MYELOID LEUKEMIA; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ACUTE DISEASE; AMINOGLYCOSIDES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE; ENEDIYNES; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOID; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 33644860896     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05872.x     Document Type: Review

References (82)

1. Alvarado Y. Tsimberidou A. Kantarjian H. Cortes J. Garcia-Manero G. Faderl S. Thomas D. Estey E. Giles F.J. 2003 Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia Cancer Chemotherapy and Pharmacology 51 87 90
2. Amadori S. Suciu S. Willemze R. Mandelli F. Selleslag D. Stauder R. Ho A. Denzlinger C. Leone G. Fabris P. Muus P. Vignetti M. Hagemeijer A. Beeldens F. Anak O. De Witte T. 2004 Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups Haematologica 89 950 956
3. Amadori S. Suciu S. Stasi R. Willemze R. Mandelli F. Selleslag D. Denzlinger C. Muus P. Stauder R. Berneman Z. Pruijt J. Nobile F. Cassibba V. Marie J.P. Beeldens F. Baila L. Vignetti M. de Witte T. 2005 Gemtuzumab ozogamicin as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups Leukemia 19 1768 1773
4. Amico D. Barbui A.M. Erba E. Rambaldi A. Introna M. Golay J. 2003 Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3 Blood 101 4589 4597
5. Andrews R.G. Torok-Storb B. Bernstein I.D. 1983 Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies Blood 62 124 132
6. Andrews R.G. Takahashi M. Segal G.M. Powell J.S. Bernstein I.D. Singer J.W. 1986 The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors Blood 68 1030 1035
7. Apostolidou E. Cortes J. Tsimberidou A. Estey E. Kantarjian H. Giles F.J. 2003 Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia Leukemia Research 27 887 891
8. Arceci R.J. Sande J. Lange B. Shannon K. Franklin J. Hutchinson R. Vik T.A. Flowers D. Aplenc R. Berger M.S. Sherman M.L. Smith F.O. Bernstein I. Sievers E.L. 2005 Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia Blood 106 1183 1188
9. Balduzzi A. Rossi V. Corral L. Bonanomi S. Longoni D. Rovelli A. Conter V. Biondi A. Uderzo C. 2003 Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation Leukemia 17 2247 2248
10. Bearman S.I. 2000 Veno-occlusive disease of the liver Current Opinion in Oncology 12 103 109
11. Berger M.S. Leopold L.H. Dowell J.A. Korth-Bradley J.M. Sherman M.L. 2002 Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse Investigational New Drugs 20 395 406
12. Bernstein I.D. 2000 Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate Leukemia 14 474 475
13. Bross P.F. Beitz J. Chen G. Chen X.H. Duffy E. Kieffer L. Roy S. Sridhara R. Rahman A. Williams G. Pazdur R. 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clinical Cancer Research 7 1490 1496
14. Buckwalter M. Dowell J.A. Korth-Bradley J. Gorovits B. Mayer P.R. 2004 Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia Journal of Clinical Pharmacology 44 873 880
15. Burnett A.K. 1998 Transplantation in first remission of acute myeloid leukemia New England Journal of Medicine 339 1698 1700
16. Cohen A.D. Luger S.M. Sickles C. Mangan P.A. Porter D.L. Schuster S.J. Tsai D.E. Nasta S. Gewirtz A.M. Stadtmauer E.A. 2002 Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease Bone Marrow Transplantation 30 23 28
17. Cortes J. Tsimberidou A.M. Alvarez R. Thomas D. Beran M. Kantarjian H. Estey E. Giles F.J. 2002 Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia Cancer Chemotherapy and Pharmacology 50 497 500
18. Cotter M. Rooney S. O'Marcaigh A. Smith O.P. 2003 Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia British Journal of Haematology 122 687 688
19. De Angelo D. Stone R. Durant S. Liu D. Baccarani M. Schiffer C.A. Amrein P. Sherman M.L. Mylotarg Study Group 2003 Gemtuzumab ozogamicin in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials [abstract] Blood 102 100a
20. Dinndorf P.A. Andrews R.G. Benjamin D. Ridgway D. Wolff L. Bernstein I.D. 1986 Expression of normal myeloid-associated antigens by acute leukemia cells Blood 67 1048 1053
21. Dowell J.A. Korth-Bradley J. Liu H. King S.P. Berger M.S. 2001 Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse Journal of Clinical Pharmacology 41 1206 1214
22. Estey E.H. Thall P.F. Giles F.J. Wang X.M. Cortes J.E. Beran M. Pierce S.A. Thomas D.A. Kantarjian H.M. 2002a Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside Blood 99 4343 4349
23. Estey E.H. Giles F.J. Beran M. O'Brien S. Pierce S.A. Faderl S.H. Cortes J.E. Kantarjian H.M. 2002b Experience with gemtuzumab ozogamycin (''mylotarg'') and all-trans retinoic acid in untreated acute promyelocytic leukemia Blood 99 4222 4224
24. Estey E.H. Garcia-Manero G. Giles F.J. Cortes J.E. O'Brien S. Kantarjian H.M. 2005 Clinical relevance of CRp in untreated AML [abstract] Blood in press
25. Freeman S.D. Kelm S. Barber E.K. Crocker P.R. 1995 Characterization of CD33 as a new member of the sialo adhesin family of cellular interaction molecules Blood 85 2005 2012
26. Gao Z. McAlister V.C. Williams G.M. 2001 Repopulation of liver endothelium by bone-marrow-derived cells Lancet 357 932 933
27. Giles F.J. Kantarjian H.M. Kornblau S.M. Thomas D.A. Garcia-Manero G. Waddelow T.A. David C.L. Phan A.T. Colburn D.E. Rashid A. Estey E.H. 2001 Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 92 406 413
28. Giles F. Garcia-Manero G. Cortes J. Thomas D. Kantarjian H. Estey E. 2002 Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy Haematologica 87 1114 1116
29. Giles F.J. Cortes J.E. Halliburton T.A. Mallard S.J. Estey E.H. Waddelow T.A. Lim J.T. 2003 Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions Annals of Pharmacotherapy 37 1182 1185
30. Golay J. Di Gaetano N. Amico D. Cittera E. Barbui A.M. Giavazzi R. Biondi A. Rambaldi A. Introna M. 2005 Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo British Journal of Haematology 128 310 317
31. Griffin J.D. Linch D. Sabbath K. Larcom P. Schlossman S.F. 1984 A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leukemia Research 8 521 534
32. Hamann P.R. Hinman L.M. Beyer C.F. Lindh D. Upeslacis J. Flowers D.A. Bernstein I. 2002 An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker Bioconjugate Chemistry 13 40 46
33. Hinman L.M. Hamann P.R. Wallace R. Menendez A.T. Durr F.E. Upeslacis J. 1993 Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Research 53 3336 3342
34. Jedema I. Barge R.M. van der Velden V.H. Nijmeijer B.A. van Dongen J.J. Willemze R. Falkenburg J.H. 2004 Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia 18 316 325
35. Jilani I. Estey E. Huh Y. Joe Y. Manshouri T. Yared M. Giles F. Kantarjian H. Cortes J. Thomas D. Keating M. Freireich E. Albitar M. 2002 Differences in CD33 intensity between various myeloid neoplasms American Journal of Clinical Pathology 118 560 566
36. Jurcic J.G. Caron P.C. Nikula T.K. Papadopoulos E.B. Finn R.D. Gansow O.A. Miller Jr. W.H. Geerlings M.W. Warrell Jr. R.P. Larson S.M. 1995 Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Research 55 5908s 5910s
37. Kell W.J. Burnett A.K. Chopra R. Yin J.A. Clark R.E. Rohatiner A. Culligan D. Hunter A. Prentice A.G. Milligan D.W. 2003 A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 102 4277 4283
38. van der Kolk D.M. de Vries E.G. Muller M. Vellenga E. 2002 The role of drug efflux pumps in acute myeloid leukemia Leukemia and Lymphoma 43 685 701
39. Larson R.A. Boogaerts M. Estey E. Karanes C. Stadtmauer E.A. Sievers E.L. Mineur P. Bennett J.M. Berger M.S. Eten C.B. Munteanu M. Loken M.R. Van Dongen J.J. Bernstein I.D. Appelbaum F.R. 2002 Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 1627 1636
40. Larson R.A. Sievers E.L. Stadtmauer E.A. Lowenberg B. Estey E.H. Dombret H. Theobald M. Voliotis D. Bennett J.M. Richie M. Leopold L.H. Berger M.S. Sherman M.L. Loken M.R. van Dongen J.J. Bernstein I.D. Appelbaum F.R. 2005 Final report of the efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 104 1442 1452
41. Leone G. Rutella S. Voso M.T. Fianchi L. Scardocci A. Pagano L. 2004 In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study Haematologica 89 634 636
42. Linenberger M.L. 2005 CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance Leukemia 19 176 182
43. Linenberger M.L. Hong T. Flowers D. Sievers E.L. Gooley T.A. Bennett J.M. Berger M.S. Leopold L.H. Appelbaum F.R. Bernstein I.D. 2001 Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 988 994
44. Lo-Coco F. Cimino G. Breccia M. Noguera N.I. Diverio D. Finolezzi E. Pogliani E.M. Di Bona E. Micalizzi C. Kropp M. Venditti A. Tafuri A. Mandelli F. 2004 Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood 104 1995 1999
45. Matsui H. Takeshita A. Naito K. Shinjo K. Shigeno K. Maekawa M. Yamakawa Y. Tanimoto M. Kobayashi M. Ohnishi K. Ohno R. 2002 Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers Leukemia 16 813 819
46. Nabhan C. Rundhaugen L. Jatoi M. Riley M.B. Boehlke L. Peterson L.C. Tallman M.S. 2004 Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease Annals of Oncology 15 1231 1236
47. Nabhan C. Rundhaugen L.M. Riley M.B. Rademaker A. Boehlke L. Jatoi M. Tallman M.S. 2005 Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older Leukemia Research 29 53 57
48. Naito K. Takeshita A. Shigeno K. Nakamura S. Fujisawa S. Shinjo K. Yoshida H. Ohnishi K. Mori M. Terakawa S. Ohno R. 2000 Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines Leukemia 14 1436 1443
49. Neumeister P. Eibl M. Zinke-Cerwenka W. Scarpatetti M. Sill H. Linkesch W. 2001 Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate Annals of Hematology 80 119 120
50. Paietta E. Andersen J. Racevskis J. Gallagher R. Bennett J. Yunis J. Cassileth P. Wiernik P.H. 1994 Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses Leukemia 8 968 973
51. Peiper S.C. Ashmun R.A. Look A.T. 1988 Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen Blood 72 314 321
52. Petti M.C. Pinazzi M.B. Diverio D. Romano A. Petrucci M.T. De Santis S. Meloni G. Tafuri A. Mandelli F. Lo Coco F. 2001 Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676) British Journal of Haematology 115 63 65
53. Piccaluga P.P. Martinelli G. Rondoni M. Malagola M. Gaitani S. Isidori A. Bonini A. Gugliotta L. Luppi M. Morselli M. Sparaventi G. Visani G. Baccarani M. 2004 Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas Leukemia and Lymphoma 45 1791 1795
54. Putti M.C. Rondelli R. Cocito M.G. Arico M. Sainati L. Conter V. Guglielmi C. Cantu-Rajnoldi A. Consolini R. Pession A. Zanesco L. Masera G. Biondi A. Basso G. 1998 Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies Blood 92 795 801
55. Rajvanshi P. Shulman H.M. Sievers E.L. McDonald G.B. 2002 Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy Blood 99 2310 2314
56. Robertson M.J. Soiffer R.J. Freedman A.S. Rabinowe S.L. Anderson K.C. Ervin T.J. Murray C. Dear K. Griffin J.D. Nadler L.M. 1992 Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia Blood 79 2229 2236
57. Saviola A. Luppi M. Potenza L. Morselli M. Ferrari A. Riva G. Torelli G. 2003 Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide British Journal of Haematology 123 752 753
58. Scheimberg I.B. Pollock D.J. Collins P.W. Doran H.M. Newland A.C. van der Walt J.D. 1995 Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies Histopathology 26 311 321
59. Scheinberg D.A. Tanimoto M. McKenzie S. Strife A. Old L.J. Clarkson B.D. 1989 Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia Leukemia 3 440 445
60. Scheinberg D.A. Lovett D. Divgi C.R. Graham M.C. Berman E. Pentlow K. Feirt N. Finn R.D. Clarkson B.D. Gee T.S. 1991 A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide Journal of Clinical Oncology 9 478 490
61. Sievers E.L. Appelbaum F.R. Spielberger R.T. Forman S.J. Flowers D. Smith F.O. Shannon-Dorcy K. Berger M.S. Bernstein I.D. 1999 Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 93 3678 3684
62. Sievers E.L. Larson R.A. Stadtmauer E.A. Estey E. Lowenberg B. Dombret H. Karanes C. Theobald M. Bennett J.M. Sherman M.L. Berger M.S. Eten C.B. Loken M.R. van Dongen J.J. Bernstein I.D. Appelbaum F.R. Mylotarg Study Group 2001 Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse Journal of Clinical Oncology 19 3244 3254
63. Simmons D. Seed B. 1988 Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells Journal of Immunology 141 2797 2800
64. Stone R.M. O'Donnell M.R. Sekeres M.A. 2004 Acute myeloid leukemia Hematology (American Society of Hematology. Education Program) 98 117
65. Takeshita A. Shinjo K. Naito K. Matsui H. Sahara N. Shigeno K. Horii T. Shirai N. Maekawa M. Ohnishi K. Naoe T. Ohno R. 2005 Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells Leukemia 19 1306 1311
66. Talpaz M. Kantarjian K. Freireich E. Lopez V. Zhang W. Cortes-Franco J. Scheinberg D. Rosenblum M.G. 2003 Phase I clinical trial of the anti-CD-33 immunotoxin HuM195/rGel [abstract] Proceedings of the American Association for Cancer Research 44 1228
67. Tchilian E.Z. Beverley P.C. Young B.D. Watt S.M. 1994 Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen Blood 83 3188 3198
68. Terstappen L.W. Safford M. Konemann S. Loken M.R. Zurlutter K. Buchner T. Hiddemann W. Wormann B. 1992 Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis Leukemia 6 70 80
69. Tsimberidou A. Estey E. Cortes J. Thomas D. Faderl S. Verstovsek S. Garcia-Manero G. Keating M. Albitar M. O'Brien S. Kantarjian H. Giles F. 2003a Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes Cancer 97 1481 1487
70. Tsimberidou A.M. Estey E. Cortes J.E. Garcia-Manero G. Faderl S. Verstovsek S. Thomas D.A. Ferrajoli A. Keating M.J. O'Brien S. Kantarjian H.M. Giles F.J. 2003b Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia Cancer Chemotherapy and Pharmacology 52 449 452
71. Tsimberidou A. Cortes J. Thomas D. Garcia-Manero G. Verstovsek S. Faderl S. Albitar M. Kantarjian H. Estey E. Giles F.J. 2003c Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Leukemia Research 27 893 897
72. Tsimberidou A.M. Estey E. Whitman G.J. Dryden M.J. Ratnam S. Pierce S. Faderl S. Giles F. Kantarjian H.M. Garcia-Manero G. 2004 Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies Leukemia Research 28 991 994
73. van der Velden V.H. te Marvelde J.G. Hoogeveen P.G. Bernstein I.D. Houtsmuller A.B. Berger M.S. van Dongen J.J. 2001 Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Blood 97 3197 3204
74. van der Velden V.H. Boeckx N. Jedema I. te Marvelde J.G. Hoogeveen P.G. Boogaerts M. van Dongen J.J. 2004 High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients Leukemia 18 983 988
75. Versluys B. Bhattacharaya R. Steward C. Cornish J. Oakhill A. Goulden N. 2004 Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure Blood 103 1968
76. Wadleigh M. Richardson P.G. Zahrieh D. Lee S.J. Cutler C. Ho V. Alyea E.P. Antin J.H. Stone R.M. Soiffer R.J. DeAngelo D.J. 2003 Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood 102 1578 1582
77. Walter R.B. Raden B.W. Hong T.C. Flowers D.A. Bernstein I.D. Linenberger M.L. 2003 Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood 102 1466 1473
78. Walter R.B. Raden B.W. Cronk M.R. Bernstein I.D. Appelbaum F.R. Banker D.E. 2004 The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood 103 4276 4284
79. Walter R.B. Raden B.W. Kamikura D.M. Cooper J.A. Bernstein I.D. 2005 Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity Blood 105 1295 1302
80. Zein N. Sinha A.M. McGahren W.J. Ellestad G.A. 1988 Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically Science 240 1198 1201
81. Zwaan C.M. Reinhardt D. Corbacioglu S. van Wering E.R. Bokkerink J.P. Tissing W.J. Samuelsson U. Feingold J. Creutzig U. Kaspers G.J. 2003a Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis Blood 101 3868 3871
82. Zwaan C.M. Reinhardt D. Jurgens H. Huismans D.R. Hahlen K. Smith O.P. Biondi A. van Wering E.R. Feingold J. Kaspers G.J. 2003b Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin Leukemia 17 468 470